Optimal management of giant cell arteritis and polymyalgia rheumatica by Rodger, Charlton
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in:
Therapeutics and Clinical Risk Management
                                                   
   
Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa10766
_____________________________________________________________
 
Paper:
Charlton, R. (2012).  Optimal management of giant cell arteritis and polymyalgia rheumatica. Therapeutics and Clinical
Risk Management, 173
http://dx.doi.org/10.2147/TCRM.S13088
 
 
 
 
 
 
Released under the terms of a Creative Commons Attribution - Non Commercial License (CC-BY-NC). 
 
_____________________________________________________________
  
This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder.
 
Permission for multiple reproductions should be obtained from the original author.
 
Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the
repository.
 
http://www.swansea.ac.uk/library/researchsupport/ris-support/ 
 © 2012 Charlton, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Therapeutics and Clinical Risk Management 2012:8 173–179
Therapeutics and Clinical Risk Management
Optimal management of giant cell arteritis  
and polymyalgia rheumatica
Rodger Charlton
College of Medicine, Swansea 
University, Wales, UK
Correspondence: Rodger Charlton 
College of Medicine, Grove Building, 
Swansea University, Swansea SA2 8PP, 
Wales, UK 
Email r.c.charlton@swansea.ac.uk
Abstract: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are clinical diagnoses 
without “gold standard” serological or histological tests, excluding temporal artery biopsy 
for GCA. Further, other conditions may mimic GCA and PMR. Treatment with 10–20 mg of 
prednisolone daily is suggested for PMR or 40–60 mg daily for GCA when temporal arteritis 
is suspected. This ocular involvement of GCA should be treated as a medical emergency to 
prevent possible blindness and steroids should be commenced immediately. There are no 
absolute guidelines as to the dose or duration of administration; the therapeutics of treating 
this condition and the rate of reduction of prednisolone should be adjusted depending on the 
individual’s response and with consideration of the multiple risks of high-dose and long-term 
glucocorticoids. Optimal management may need to consider the role of low-dose aspirin in 
reducing complications. Clinicians should also be aware of studies that indicate an increased 
incidence of large-artery complications with GCA. This clinical area requires further research 
through future development of radiological imaging to aid the diagnosis and produce a clearer 
consensus relating to diagnosis and treatment.
Keywords: arteritis, visual loss, blindness, erythrocyte sedimentation rate, stiffness, pain, 
aspirin, disability, glucocorticoids
Introduction
Giant cell arteritis (GCA) is linked with polymyalgia rheumatica (PMR). The overlap 
is considerable as 16%–21% of patients with PMR have GCA on temporal artery 
biopsy and symptoms of PMR are present in 40%–60% of patients with GCA.1 The 
peak incidence is between 60 and 75 years of age and incidence is increasing as the 
population ages. There is continuing controversy in specialist rheumatology and pri-
mary care as the optimal diagnosis and management of GCA are difficult, not least 
because of the syndrome’s presentation as temporal arteritis (TA) with its ocular 
involvement, and the risk of blindness if it is untreated or under-treated. GCA is a 
syndrome of systemic inflammation that accompanies vascular manifestations such 
as TA, also referred to as cranial arteritis. Arterial biopsies may reveal changes to the 
tunica media vasorum and tunica adventitia that cause narrowing or occlusion of the 
vessel, leading to ischemia distal to the lesion.
Although PMR is a common disorder, systematic studies of its pathophysiology, 
diagnosis, and treatment are limited.2 It has been argued that PMR and TA are clinical 
syndromes that form part of the spectrum of GCA, and so are different manifestations 
of the same disease process.3,4 Further, it has been suggested that a generic term of 
“polymyalgia arteritica” should be used where the “relatively benign” PMR may later 
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progress to GCA with its “multi-system pathological process” 
including TA.5 Although GCA, including TA, is linked with 
PMR, both conditions can occur in isolation from each other.6 
The frequency with which each of these conditions presents 
differ in each source consulted, emphasizing the difficulties 
and lack of consensus relating to diagnosis.
PMR is an inflammatory disease that usually presents 
in primary care with symmetrical aching, tenderness, and 
stiffness of the proximal muscles of the neck, shoulders, 
and pelvis, particularly in the morning, which may prevent 
a patient getting out of bed. Muscle strength is not usually 
impaired but is hindered by pain.7 Frequently, it is a diagnosis 
of exclusion based on a syndrome of symptoms and signs 
where greater clarity of diagnosis is helped through some basic 
investigations. Distinguishing GCA and PMR is important 
because GCA can lead to blindness through ocular ischemia/
anterior ischemic optic neuropathy and requires higher doses 
of glucocorticoid medication. Approximately 10% of patients 
initially presenting with PMR will have vasculitis on biopsy – 
for example, of a temporal artery – requiring a revision of their 
diagnosis. The standard treatment for PMR with low-dose 
steroids unfortunately has no prophylaxis against the blinding 
that can result from ocular involvement of GCA.8
This study now considers the optimal management 
(diagnosis and treatment) of GCA and so builds on previous 
publications by the author.9,10
Definitions
Although the histological definition of “GCA” is clearer, it 
overlaps that of “PMR,” reinforcing a statement in a study 
as long ago as 193811 on the topic of TA, which refers to the 
condition of “rheumatic arteritis” and notes that “there is 
great difficulty in making a confident separation of some of 
the forms of arteritis into groups on account of the lack of 
knowledge about the causation.”
The term “PMR” has an interesting history. It was not 
until 1957 that Barber tentatively suggested the term “poly-
myalgia rheumatic” for this collection of symptoms and 
signs.12 Prior to this, descriptions of the same clinical picture 
were given names such as “anarthritic rheumatoid disease” or 
“myalgic syndrome of the aged with systemic reaction.”13
Attempting to distinguish PMR 
from GCA
GCA can be difficult to distinguish from, or may coexist with, 
PMR, and can have the complications of blindness from its 
effect on the ophthalmic arteries (or short posterior ciliary 
arteries, which are branches of the ophthalmic artery) and 
cardiac ischemia through its effects on the coronary arteries.14 
One study makes this point well by s uggesting that GCA could 
be an “iceberg disease” with obvious classical forms distracting 
attention from the “submerged mass of illness.”15 This study 
emphasizes the importance of palpation of the temporal arter-
ies and auscultation of main arteries for bruits in the routine 
assessment of such patients. Cheung and  Richards16 cite Stra-
chan et al14 and their proposed  clinical classification of GCA 
to improve the awareness of the diversity of this condition. It is 
suggested that there is “classic GCA” and what is described as 
“masked GCA.” In masked GCA, patients can present with:
•	 Weight loss and cachexia
•	 Pyrexia of unknown origin
•	 Anemia
•	 Aortic regurgitation
•	 Ruptured aortic aneurysm
•	 Cerebrovascular accident, myocardial ischemia, or inter-
mittent claudication (“occlusive group”).
Etiology
In the UK, GCA occurs in 2.2 per 10,000 patient years. It is 
very unlikely to occur in people aged ,50 years, and there 
is a peak incidence between the ages of 60 and 75 years.17 
The disease is almost always confined to Caucasians, with 
a higher incidence in Scandinavia and northern Europe. The 
incidence varies between 10 and 50 cases/100,000 people 
aged .50 years.3 The number of people at risk is expected to 
double in the next 25 years as the average age of the population 
 increases.18 The cause of PMR is unknown, as is the relation-
ship between PMR and GCA. In a seminar on the subject, it 
was reported that “few population-based studies have assessed 
the epidemiological aspects of polymyalgia rheumatica 
because there is a lack of a diagnostic hallmark and universally 
accepted diagnostic and classification criteria.”19
As the onset of symptoms can be quite sudden, a possible 
viral etiology has been proposed. However, “a well-defined 
infectious agent has never been found.”19 Genetic factors 
appear to be important and HLA-DR4 has been associated 
with PMR, but the etiology remains unclear.19
Symptoms
Criteria for GCA issued by the American College of 
 Rheumatology in 1990 include three or more of the 
following20:
•	 Age 50 years or older
•	 New-onset localized temporal headache
•	 Temporal artery tenderness or decreased temporal artery 
pulse
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•	 Erythrocyte sedimentation rate (ESR) of at least 50 mm/h
•	 Abnormal artery biopsy specimen characterized by 
mononuclear infiltration or granulomatous inflammation
There may also be:21
•	 Myalgia
•	 Systemic malaise
•	 Fever
The presentation varies and may include fever of unknown 
origin, visual loss, or limb claudication. The arterial lesions 
may be widespread, hence the different manifestations and 
presentations that vary according to the anatomy of the area 
affected. Indeed, the lesions may be more widespread than 
the ophthalmic artery and branches of the external carotid 
system. GCA and PMR can share similar systemic symp-
toms including tiredness, fever, and weight loss, and likely 
represent two parts of a disease spectrum. However, GCA is 
at the more severe end of this spectrum.
GCA most commonly affects the branches of the internal 
and external carotid arteries, which can lead to symptoms 
such as headache or symptoms of the associated anatomy 
such as pain while chewing, jaw, sinus, or tongue pain.18 In 
GCA, inflammation in the walls of the smaller vessels leads 
to a narrowing of the lumen and eventual occlusion where 
pain is a result of ischemia. Jaw claudication and headache 
occur in 30%–80% of cases, and visual disturbances such 
as amaurosis fugax, hallucinations, diplopia, or irreversible 
visual loss occur in ,20% of cases.22
For dentists, GCA should be considered in the differential 
diagnosis if a patient has puzzling symptoms that are not 
explained by oral findings.23 GCA often manifests as a new-
onset headache or a headache different from previous headaches. 
If the patient has a headache, particularly a temporal headache, 
or of they develop visual symptoms or scalp tenderness, GCA 
affecting the extracranial arteries (eg, the temporal arteries) 
should be considered. A temporal artery biopsy may be indicated 
to confirm the diagnosis through the presence of giant cells. 
However, glucocorticoids should be commenced urgently with 
this degree of suspicion to prevent potential loss of vision.
The loss of vision in TA results from ischemia and infarc-
tion of the optic nerve, which causes the appearance of a pale 
and swollen optic nerve head on fundoscopy.8 Appreciable 
visual loss occurs in 30%–50% of patients with untreated 
GCA, but it is very difficult to predict which patients 
with GCA will go on to develop ocular complications.24 
Occasionally, large arteries are also affected when conditions 
such as aortic dissection have been reported.25 Clinicians 
should consider the potential complications of large-artery 
disease to ensure optimal management.
Like GCA, the onset of PMR is usually acute. However, 
symptoms are generally present for longer than a month 
before patients seek advice. Many authors refer to “proximal 
girdle involvement,” and the word “girdle” may be interpreted 
as muscles that encircle the neck, shoulders, or pelvis. Two 
cardinal features of PMR are girdle pain and morning stiff-
ness lasting for over 30 minutes.7 The aching pain and stiff-
ness is usually of sudden onset and quickly becomes bilateral. 
There may also be systemic symptoms such as low-grade 
fever, fatigue, and weight loss. Transient peripheral synovitis 
of the wrists, knees, and sternoclavicular joints has also been 
documented.6 The presentation of PMR may therefore be 
symmetrical aching, tenderness, and stiffness of the proximal 
muscles of the neck, shoulders, and pelvis. These symptoms 
may be particularly pronounced in the morning and may 
prevent a patient from getting out of bed. Muscle strength is 
usually not impaired, but is hindered by pain.
Difficulty of  TA diagnosis
A diagnosis of TA can easily be missed. A 1971 Swedish 
study of 1097 consecutive autopsies included a temporal 
artery examination in each autopsy and 16 cases of undiag-
nosed GCA were identified.21 A retrospective analysis of the 
medical records provided evidence of typical features of undi-
agnosed GCA in nine.26 In addition, an audit of 65 patients 
with GCA found that 44 had had unrecognized visual distur-
bance, visual loss, or stroke a mean of 35 days between the 
onset of symptoms and diagnosis (range of 2 to 336 days).27 
Eleven of these patients presented without headache or scalp 
tenderness and ten of these had visual loss.
A meta-analysis from the USA28 was reported in a study 
that looked at studies examining the value of individual clini-
cal features in predicting positive results of temporal artery 
biopsy in patients with suspected GCA.21 Several symptoms 
were moderately predictive of a positive biopsy result 
 (likelihood ratio .2):
•	 Jaw claudication (34%) (it is recorded that claudicant pain 
comes on gradually during chewing, whereas dental pain 
is immediate)
•	 Diplopia (8%)
•	 Any abnormality on palpation of the temporal artery – 
absent, beaded, tender, or enlarged (65%) 
	 Other useful predictive features (likelihood ratio .1.5) 
were:
•	 Temporal headache
•	 Scalp tenderness
•	 ESR .100 mm/h
•	 Anemia
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Differential diagnosis
Many conditions may mimic the symptoms of PMR. For 
example, fibromyalgia, osteoarthritis, rheumatoid arthritis, 
or systemic lupus erythematosus should be considered. 
 Similarly, the possibility of an occult malignancy or sepsis 
that can present with muscle pains should form part of the dif-
ferential diagnoses. Further, a combination of osteoarthritis 
with a systematic problem such as intercurrent infection may 
appear to be PMR.6 Metabolic conditions should be excluded, 
including thyroid disease and hyperparathyroidism. The 
likelihood of such conditions is greater with a normal ESR 
on presentation, a poor response to corticosteroids, age of 
onset ,50 years, an absence of upper limb involvement, and 
a slow onset. PMR is currently a clinical diagnosis without a 
“gold standard” serological or histological test.6
This study will also consider the development of radio-
logical imaging that may benefit the diagnostic process in 
the future.
Parameters for diagnosis
A raised ESR continues to be the universal diagnostic para-
meter and the parameter by which response to treatment with 
steroids is judged and the condition monitored. The “lack of 
a gold standard bedevils the establishment” of an accurate 
diagnosis.29 If it appears that, clinically, a patient has PMR, 
C-reactive protein (CRP) should be measured as this may be 
raised in patients with a normal ESR. Measurement of the 
plasma viscosity (PV) may also be considered.30,31 The results 
of studies vary, but an ESR of at least 40 mm/h supports the 
diagnosis with associated symptoms. However, 5%–20% of 
cases may have an ESR within the normal range.16,19
There may be a mild normocytic anemia, which is 
frequently associated with chronic disease, but tests for 
rheumatoid factor and antinuclear antibodies are generally 
negative. A rapid response to steroids is an important diagnos-
tic pointer.3,7 In GCA, arteries may be thickened, tender, and 
nodular, with pulsation being absent or reduced.17 Temporal 
artery biopsy is not an investigation with a high sensitivity and 
where GCA is suspected, despite a negative biopsy, steroid 
treatment should be started.5,17 Also, it is difficult to obtain 
biopsies and biopsy results quickly.17
Mainstay of treatment
Glucocorticoids are the drug of choice. If GCA is also sus-
pected, Salvarani and colleagues suggest a dose of 40–60 mg 
of prednisolone daily, as this is the dose necessary to suppress 
the disease, and a dose of 10–20 mg daily of prednisolone 
for PMR.18,19 In GCA, if the patient has ischemic symptoms 
(jaw or tongue claudication, or visual symptoms), 60 mg 
prednisolone daily should be given. If the patient has visual 
symptoms, they should be admitted to hospital for treatment 
with intravenous methylprednisolone.21 Although there are 
no widely accepted standard treatment schedules in relation 
to the dose or its duration, there are helpful British Society 
for Rheumatology (BSR) and British Health Professionals in 
Rheumatology (BHPR) guidelines.32 Essentially, the amount 
of prednisolone can be reduced once symptoms have eased 
(which they usually do quickly) and the ESR has normalized. 
If symptoms start to relapse, then the reduction in dose has 
been too soon.
Clinical risk management
A patient presenting with sudden loss of vision in one or 
both eyes should be given an intravenous injection of 10 mg 
dexamethasone because of the risk of permanent blindness.5 
Treatment with glucocorticoids is mandatory for GCA 
to prevent vascular complications and treatment may be 
required for 3–4 years, with relapses most likely in the first 
18 months of treatment. Relapses may occur in a third or more 
of patients and should be treated by a dose of prednisolone 
the same or greater than that given before relapse, depending 
on the severity of symptoms.17 Relapse is associated with 
rapid tapering of the dose;6 to prevent this, where a patient 
is on 15 mg (for example), this should be maintained for 
4 weeks and then reduced to 12.5 mg for another 4 weeks. 
When a dose of 10 mg is reached, it should be reduced by 
1 mg every 4–8 weeks, with the rate of reduction adjusted 
depending on the response. The dose, length of treatment, 
and rate of reduction are based largely on observational 
studies. There should, however, be a dramatic response to 
treatment within a few days, and tapering of the dose should 
be individualized.6,18 The BSR and BHPR guidelines should 
be consulted for optimal treatment.32
There are many potential side effects of glucocorticoids, 
which, paradoxically, can lead to weakness rising from sitting, 
or falls.18 The following list of side effects demonstrates how 
it is important to monitor blood glucose with ESR measure-
ments and to put in place measures to prevent osteoporosis. 
Side effects of treatment with glucocorticoids may include:
Acute
•	 Risk of peptic ulceration is increased in patients who are 
concurrently receiving nonsteroidal anti-inflammatory 
drugs or aspirin
•	 Infection through suppression of the immune response
•	 Reduced potassium leading to muscle weakness
•	 Increased sodium
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•	 Sleep disturbance
•	 Confusional states
Long-term
•	 Osteoporosis
•	 Addisonian crisis with rapid withdrawal
•	 Reduced glucose tolerance and diabetes
•	 Corticosteroid myopathy
Patients should be made aware of possible side effects 
of glucocorticoids and should alert other health care practi-
tioners that they are on glucocorticoids, as there will be an 
increased risk of infection or gastrointestinal bleeding. As 
patients may be on glucocorticoids for some time, it is appro-
priate to consider prophylaxis with calcium and vitamin D, as 
well as other treatment, such as a bisphosphonate for those 
found to have osteopenia or osteoporosis. Ideally, concomi-
tant bisphosphonate and calcium/vitamin D therapy should 
be prescribed when glucocorticoid treatment begins. This is 
particularly important because GCA and PMR may occur in 
older people who are already at greater risk of osteoporosis. 
Helpful guidelines for the management of glucocorticoid-
induced osteoporosis are provided in the 2010 American 
College of Rheumatology recommendations.33
An alternative treatment is intramuscular or intravenous 
methylprednisolone acetate, for which a lower incidence of 
glucocorticoid-related side effects has been documented.6 
If intramuscular or intravenous methylprednisolone pulse 
therapy is administered, there is evidence of reduced inci-
dence of GCA complications, including visual loss.34 In addi-
tion, the use of pulse therapy in the initial treatment of GCA 
allows for a more rapid tapering of oral glucocorticoids, less 
likelihood of relapse, and reduced potential for the long-term 
side effects of treatment with oral glucocorticoids.35
The use of glucocorticoid-sparing agents, such as metho-
trexate, azathioprine, cyclophosphamide, and cyclosporine, 
may be useful in reducing the side effects of glucocorticoids. 
However, due to a lack of data, no conclusive recommenda-
tions can be made.23
Cerebrovascular accidents and visual loss are  potential 
causes of morbidity with GCA and are due to cranial 
 ischemia. One study suggests that the use of low-dose 
aspirin in addition to corticosteroid therapy may lessen the 
risk of these complications, and this is recommended by the 
 European League Against Rheumatism.36
Duration of treatment
As relapses are more likely to occur during the initial 
18 months of therapy and within 1 year of glucocorticoid 
withdrawal, all patients should be monitored for symptom 
recurrence throughout corticosteroid tapering and until 
12 months after therapy cessation. Approximately 50%–75% 
of patients can discontinue glucocorticoid therapy after 
2 years of treatment. This is a controversial area of rheumato-
logical practice, as it is an ongoing challenge – no consensus 
has been reached about optimal management and further 
research is required.
Outcomes of disease process  
and prognosis
GCA and PMR are self-limiting conditions that usually last 
2 years, but there have been reports of cases persisting for 
up to 7 years.37 It was reported in 1979 that “the difficulty 
often lies not in starting treatment but in deciding how long 
it should continue.”38 There is a need for a careful assessment 
to maintain an acceptable balance between the benefits and 
risks of long-term glucocorticoid therapy.25 Acute blind-
ness occurs in up to 20% of patients with GCA.4 Delay in 
recognition may explain the high incidence of irreversible 
loss of vision, which is preventable with early diagnosis and 
treatment.21
Optimal management of PMR and GCA should take 
into account studies indicating an increased incidence 
of large-artery complications including aortic aneurysm, 
 aortic dissection, and large-artery stenosis. In the USA, one 
population-based study from 1950 over 50 years identi-
fied 46 cases of large-artery complication in 168 patients, 
which represents 27% of the cohort studied.39 It has been 
suggested that large-artery involvement is common in GCA 
and that early intervention with glucocorticoid therapy is 
appropriate.40
Future developments
Future diagnostic techniques may be enhanced by technologi-
cal improvements in radiological imaging. In PMR, routine 
X-rays do not usually reveal any abnormalities. However, 
magnetic resonance imaging (MRI) has demonstrated that 
PMR involves inflammation of extra-articular synovial 
structures and, in particular, that MRI scans of the shoulder 
show bilateral subacromial and subdeltoid bursitis in nearly 
all patients with active PMR.41 Similarly, ultrasonography 
often reveals effusions within both shoulder bursae in patients 
with PMR.42
The role of positron emission tomography (PET) scanning 
is less clear but may indicate that subclinical inflammation 
of the great vessels is more common than previously sup-
posed in PMR.43 The sensitivity and specificity and, thus, 
 interpretations of the findings from these investigations 
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in relation to GCA need to be agreed and validated. It has 
been suggested that these investigations will lead to “a 
new era where our understanding of the extent of vascular 
involvement in GCA may become more precise.”44 This has 
implications for both diagnosis and management, subject to 
the ready availability of these investigations, their speed, and 
their affordability.
Conclusion
Few population-based studies have assessed the epidemio-
logical aspects of GCA and PMR because there is a lack of a 
diagnostic hallmark and universally accepted diagnostic and 
classification criteria. There remain many unknowns in the 
diagnosis and treatment of GCA, and its overlap with PMR. 
It remains a challenge and an area requiring further research. 
However, appropriate use of glucocorticoids remains the 
cornerstone of treatment.22,32,33
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